Press
Ivím in the News
Ivím Health Study Featured in Medscape: Are We Prescribing GLP-1s Wrong?
Medscape covers Ivím’s published research and the question of whether standard GLP-1 prescribing leaves results on the table.
Dr. Jessica Duncan on GLP-1 Weight Regain: Why Stopping Medication Leads to Weight Return
Ivím’s CMO explains for KevinMD why weight often returns after GLP-1 medication is stopped.
Two peer-reviewed studies published in Obesity Pillars report that Ivim Health patients receiving GLP-1 therapy within a comprehensive care protocol achieved up to 26.54% average weight loss
Announcement of Ivím’s two Obesity Pillars studies on GLP-1 outcomes under its comprehensive care protocol.
Dr. Jessica Duncan Shares Perspective on Updated Dietary Guidelines in 2026
Dr. Duncan discusses the 2026 update to U.S. dietary guidelines on The David Webb Show.
Dr. Jessica Duncan on The David Webb Show
Podcast interview with Ivím’s Chief Medical Officer on obesity medicine and patient care.
Ivim Health Unveils GLP-1 ID: Precision Dosing Meets Individualized Care
Ivím launches GLP-1 ID, its program for individualized GLP-1 dosing.
New IVIM Study Shows 21.8% Average Weight Loss Over 68 Weeks
Ivím announces results from its semaglutide outcomes study covering 68 weeks of treatment.
Ivím at Work Named Gold Stevie® Award Winner in 2025 American Business Awards®
Ivím’s corporate wellness program earns a Gold Stevie at the 2025 American Business Awards.
Ivim Health Supports the Outsourcing Facilities Association's Appeal of Court Ruling
Ivím backs an industry appeal of a court ruling that restricts access to compounded GLP-1 medications.
Ivím Health Raises Alarm as FDA Deadline Threatens Obesity Treatment Access
Ivím warns that an approaching FDA deadline could cut patients off from obesity treatment.